Key Stats for Vertex Pharmaceuticals Stock
- 52-Week Range: $363 to $511
- Current Price: $430
- Street Mean Target: $548
- Street High Target: $641
- TIKR Model Target (Dec. 2030): $835
What Happened?
Vertex Pharmaceuticals (VRTX), the Boston-based biopharmaceutical company best known for dominating the cystic fibrosis market, closed 2025 with total revenue of $12 billion, a 9% increase year-over-year.
Q4 revenue hit $3.2 billion, up 10% compared to the same quarter in 2024.
The CF franchise, which remains the company’s primary revenue engine, grew 7% for the full year, with U.S. CF revenue up 11% driven by pediatric uptake, TRIKAFTA strength, and higher net prices.
Two new commercial products added meaningful diversification: CASGEVY, the gene-editing therapy for sickle cell disease and beta thalassemia, generated $116 million in full-year revenue, while JOURNAVX, the non-opioid acute pain drug launched in early 2025, delivered $60 million in its first eight months on market.
Q4 non-GAAP EPS came in at $5.03, a 26% increase versus the prior year, against a Street estimate of $5.07.
Full-year non-GAAP EPS reached $18.40, and the company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities.
On the Q4 2025 call, CEO Reshma Kewalramani described the company’s position plainly: “2025 was marked by excellent progress across the business, disciplined commercial execution in CF and the new product launches, meaningful pipeline progress and robust financial performance.”
For 2026, Vertex guided to total revenue of $12.95 billion to $13.1 billion, representing 8% to 9% growth, with non-CF products expected to contribute at least $500 million.
JOURNAVX prescriptions are expected to more than triple versus the approximately 550,000 written in 2025, with revenue conversion improving as gross-to-net normalizes through the year.
The pipeline catalyst that matters most is povetacicept, or pove, an experimental drug for IgA nephropathy (IgAN), a progressive autoimmune kidney disease affecting 330,000 patients in the U.S. and Europe.
On March 10, Vertex announced that pove met its primary endpoint and all secondary endpoints in the Phase 3 RAINIER trial, reducing urinary protein-to-creatinine ratio (UPCR, a key marker of kidney damage) by 52% at 36 weeks versus a 4.3% decline for placebo.
The FDA BLA submission for pove was completed by end of March, with a priority review voucher in place targeting a six-month regulatory review window.
On April 1, the FDA expanded the label for both ALYFTREK and TRIKAFTA, extending CFTR modulator eligibility to approximately 95% of all U.S. CF patients.
Wall Street’s Take on VRTX Stock
Vertex pharmaceuticals stock entered 2026 with a CF franchise compounding at high single digits and two new commercial launches finding their footing, but the pove data in March reset the investment conversation entirely.
Of 32 analysts covering the stock, 21 rate it a buy, 5 an outperform, 5 a hold, 1 an underperform, and 1 a sell, with a mean price target of $548 implying approximately 27% upside from the current price of $430.
The target range runs from $330 to $641, with the upper end anchored by analysts who model pove becoming a multi-indication blockbuster across IgAN, membranous nephropathy, and myasthenia gravis.
Maxim Group upgraded VRTX stock to buy after the pove Phase 3 readout, raising its price target to $575 and calling the drug a potential blockbuster that could diversify revenue well beyond CF.
BMO raised its target to $600, citing the 36-week RAINIER data as showing “robust efficacy” and positioning pove as a “clear competitor and potential leader” in IgAN.
The risk the model depends on is gross-to-net normalization for JOURNAVX: management explicitly stated that the patient support program will sunset in late 2026 to early 2027, and if payer coverage gaps persist longer than expected, prescription growth will not convert to revenue as quickly as the 2026 guide implies.
The catalyst to watch is the Q1 2026 earnings release on May 4, where JOURNAVX revenue will give the first read on whether the prescription tripling trajectory is tracking, and any pove FDA acceptance update will set the commercial launch clock.
What Does the Valuation Model Say?
The TIKR model prices Vertex stock at $835, implying 94% upside from current levels, built on a mid-case revenue CAGR of around 11% through 2030 and net income margins expanding toward around 43%, assumptions grounded in CF durability, JOURNAVX scaling, and pove entering the IgAN market.
At roughly 23x forward EPS for a business with five commercial products, a patent-protected CF franchise running past 2037, and a renal pipeline that management believes will ultimately rival CF in scale, Vertex Pharmaceuticals stock appears undervalued relative to what the next three years of catalysts could unlock.
The central tension in the Vertex investment case is sequencing: the company must convert JOURNAVX prescription momentum into revenue while simultaneously launching pove, and the market is discounting both on the assumption that execution will lag the pipeline.
What Has to Go Right
- JOURNAVX prescriptions triple in 2026 as guided (from approximately 550,000 to 1.6+ million), with gross-to-net normalizing by late 2026 and revenue conversion accelerating into 2027
- Pove receives FDA accelerated approval in late 2026 or early 2027, with 74 payer engagements covering 210+ million lives already in progress providing near-launch access
- CF franchise sustains 7% to 9% annual growth through younger age group expansion, geographic penetration (1,500 newly eligible patients in Italy alone with ALYFTREK), and ALYFTREK transitions
- VX-828 Phase 1b data, expected in the second half of 2026, confirms next-gen 3.0 CF potential, extending the franchise’s runway well beyond the 2037 TRIKAFTA core patent
What Could Go Wrong
- JOURNAVX gross-to-net does not normalize on the guided timeline, leaving the $500 million non-CF revenue target underpowered and 2026 EPS consensus of around $19 at risk
- Pove IgAN label comes in narrower than expected, limiting the addressable patient population in the U.S. launch window before full approval data arrives at 104 weeks
- Competitive pressure in IgAN intensifies, with Otsuka’s Voyxact and Vera Therapeutics’ atacicept already on market or in late-stage development, compressing pove’s peak share assumptions
- CASGEVY revenue remains lumpy quarter-to-quarter as patients self-select infusion timing, making near-term revenue visibility for the gene therapy franchise difficult to model with precision
Should You Invest in Vertex Pharmaceuticals Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up VRTX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Vertex Pharmaceuticals Incorporated alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze VRTX stock on TIKR for Free →
